WO1996039107A1 - Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices - Google Patents
Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices Download PDFInfo
- Publication number
- WO1996039107A1 WO1996039107A1 PCT/US1996/008515 US9608515W WO9639107A1 WO 1996039107 A1 WO1996039107 A1 WO 1996039107A1 US 9608515 W US9608515 W US 9608515W WO 9639107 A1 WO9639107 A1 WO 9639107A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cement
- bone
- bisphosphonate
- alendronate
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
- A61F2002/4631—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor the prosthesis being specially adapted for being cemented
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/112—Phosphorus-containing compounds, e.g. phosphates, phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the instant invention relates to the use of bisphosphonate salts, e.g., alendronate, in an acrylate-based polymer bone cement such as polymethylmethacrylate (PMMA), to prevent periprosthetic bone loss and failure of a joint prosthesis and in arthroplasty patients having an orthopedic implant device.
- bisphosphonate salts e.g., alendronate
- PMMA polymethylmethacrylate
- a bone resorption inhibitor into the implant cement, which binds (fixates) the device to the supporting trabecular or cortical bone in the cavity in which the bone is inserted.
- the presence of a bone resorption inhibitor should sufficiently inhibit bone resorption in the periprosthetic area of the implant device to obviate replacement surgery.
- Most of the currently new bone resorption inhibitors are non-estrogenic therapeutic agents in the class of bisphosphonates.
- US Patent No. 4,621,077, issued Nov. 4, 1986 to Rosini and Staibano discloses pharmaceutical compositions comprising (4- amino-l-hydroxybutylidene-l,l -bisphosphonic acid (ABP) or a water-soluble (sodium, aniline or lysine) salt thereof.
- ABSP (4- amino-l-hydroxybutylidene-l,l -bisphosphonic acid
- Alendronate, 4-amino-l-hydroxybutylidene-l,l- bisphosphonic acid monosodium trihydrate is a known bone resorption inhibitor and is described in U.S. Patents 4,922,007 and
- Clodronate (dichloromethylene)bisphosphonic acid disodium salt (Proctor and Gamble, is described in Belgium Patent
- Tiludronate ([(4-chlorophenyl)thiomethylene]- bisphosphonic acid) (Sanofi) is described in U.S. Patent 4,876,248 issued October 24, 1989.
- CGP 42'446 being 2-(imidazol-l-yl)-hydroxyethyl- idene-l,l-bisphosphonic acid is a Ciba Geigy compound and is described in Bone and Mineral, Abstracts, Supplement 1 to Vol 25, April 1994, S61 , Article 12, by A. Pataki et al. Ibandronate, BM 21.0995 (l-Hydroxy-3-(methylpentyl- amino)-propylidene-bisphosphonate) by Boehringer-Mannheim - is described in U.S. Patent 4,927,814 issued May 22, 1990.
- Mildronate a derivative of pamidronate, 3-(N,N- dimethyl)amino-l -hydroxy-propylidene-bisphosphonic acid, dimethyl-APD, is described in Bone and Mineral, Abstracts, Supplement 1 to Vol 25, April 1994, S79, Article 78, by D. Gonzalez et al.
- piridronate Another Proctor and Gamble compound, piridronate.
- [2-(2-pyridinyl)ethylidene]-bisphosphonic acid, monosodium salt is described in USP 4,761 ,406 as having bone resorption inhibition activity.
- Quaternary nitrogen derivatives of piridronate, including NE-58051 , NE-58095, NE-58043, NE-10244, NE-1-0446 are described in Bone and Mineral, Abstracts, Supplement 1 to Vol 25, April 1994, S65, Article 24, by F. H.Ebetino et al.
- the article, "Monatschefte" 99, 2016 (1968) by F. Kasparet describes the synthesis of etidronate. (1-hydroxy- ethylidene)bisphosphonic acid, disodium salt, (Proctor and Gamble).
- US Patent No. 4,446,052 issued May 1, 1984 to Sunberg and Benedict, discloses a gel comprising di[(3-amino-l- hydroxy-propylidene)- 1 , 1 -bisphosphonic acidjtricalcium salt in water.
- the gel is disclosed to be useful for the treatment of certain disorders of calcium metabolism in warm blooded animals.
- a bone implant cement to optimally prevent excessive bone resorption in the periprosthetic area of an implant device, i.e., the bone area which is in contact and close proximity to the cement surface, to retard the aseptic loosening and failure of the device and thereby to prevent the pain, morbidity and cost associated with this condition.
- a bisphosphonate salt can be used in a bone fixation cement for patients for the prevention of failure of joint prostheses, e.g., for the hip or knee.
- Administration of a fixation cement containing a bisphosphonate, e.g., alendronate can provide extended therapeutic action and prevent the periprosthetic bone resorption process and thereby maintain the integrity of the total prosthetic structure.
- a bone implant cement comprising a pharmaceutically acceptable polymeric carrier and an effective amount of a bisphosphonate bone resorption inhibitor.
- the bisphosphonate applicable in the cement includes the free acids, and pharmaceutically acceptable salts, e.g., sodium, potassium, ammonium, calcium, magnesium and barium salts of: alendronate, clodronate, tiludronate, YM 175, ibandronate (BM 21.0995), risedronate, piridronate, pamidronate, or combinations thereof.
- pharmaceutically acceptable salts e.g., sodium, potassium, ammonium, calcium, magnesium and barium salts of: alendronate, clodronate, tiludronate, YM 175, ibandronate (BM 21.0995), risedronate, piridronate, pamidronate, or combinations thereof.
- step (b) adding the cement from step (a) to the bone cavity; (c) implanting the joint prosthesis into the bone cavity.
- the bisphosphonates described above are useful in the invention cement.
- Very useful are the sodium, potassium and calcium salts of residronate, clodronate, tiludronate and alendronate and particularly useful are the sodium and calcium salts of alendronate, i.e., monosodium alendronate trihydrate, disodium alendronate, anhydrous monosodium alendronate, di[(3-amino-l- hydroxypropylidene)- 1 ,1 -bisphosphonic acid]tricalcium, [(4-amino- 1 -hydroxybutyli dene)- 1 ,1 -bisphosphonic acidjmonocalcium salt, (ABP)Ca, di[(4-amino- 1 -hydroxybutylidene)- 1 , 1 -bisphosphonic acid]monocalcium salt, (ABP)2Ca, and tri[(4-amino-l -hydroxy ⁇ butylidene
- the cement disclosed herein can be used to treat human subjects at the time of insertion of a prosthesis, i.e., a medical implant device.
- the method described herein involves the administration of a bisphosphonate fixation cement in an osteogenically effective amount to inhibit bone reso ⁇ tion in the periprosthetic bone area of a medical implant device.
- peripheral bone area as used herein is meant the area of bone which is in contact with the medical implant device, including the cement, or in the immediate proximity thereof.
- sodium alendronate as used herein, is meant alendronate, being 4-amino-l -hydroxybutylidene- 1,1- bisphosphonic acid monosodium trihydrate.
- calcium alendronate as used herein, is meant the above four listed insoluble calcium salts.
- Very useful bisphosphonates salt in the invention are alendronate and calcium alendronate.
- insoluble is meant that the aqueous solubility of the bisphosphonate, calcium alendronate, at room temperature is not appreciable.
- inhibittion of bone reso ⁇ tion refers to prevention of bone loss, especially the inhibition of removal of existing bone either from the mineral phase and/or the organic matrix phase, through direct or indirect alteration of osteoclast formation or activity.
- inhibitor of bone reso ⁇ tion refers to agents that prevent bone loss by the direct or indirect alteration of osteoclast formation or activity.
- osteoogenically effective means that amount which decreases the turnover of mature bone.
- an osteogenically effective dose is also “pharmaceutically effective.”
- subject refers to a living vertebrate animal such as a mammal in need of treatment, i.e., in need of an implant device
- preventing shall mean providing a subject with an amount of a bisphosphonate in a bone cement sufficient to act prophylactically on the bone cavity and the periprosthetic bone area to prevent the loosening of the implant device.
- cement is meant to encompass the mixed cement composition containing all of the ingredients and components prior to, during, and after complete “curing”, i.e., during early stages of monomer polymerization, at partial polymerization and complete polymerization.
- cement can include the kneaded precured mass containing unpolymerized methylmethacrylate just prior to insertion into the bone cavity, the inserted mass just after insertion, and the fully polymerized cement , i.e., "fully cured", inside the bone cavity in contact with the prosthetic bone and the implant device after sufficient time for complete curing, e.g., 15-20 minutes.
- PMMA polymethylmethacrylate
- a solid acrylate polymer part which is generally a sterile package containing fully polymerized polymer, e.g., PMMA beads of substantially uniform small particle size of about 5-20 microns average diameter, and a catalyst, e.g., a solid aromatic peroxide such as benzoyl peroxide, present in about in one weight percent or less; and a second part, containing the acrylate monomer, which is generally a sterilized ampoule containing the acrylate or methacrylate monomer, e.g., methylmethacrylate, and an initiator, e.g., an N,N-disubstituted aromatic amine such as N,N-dimethyl-p-toluidine, present in about one weight percent or less.
- a solid acrylate polymer part which is generally a sterile package containing fully polymerized polymer, e.g., PMMA beads of substantially uniform small particle size of about 5-20 microns average diameter, and a catalyst,
- the second part can also contain a small quantity of a monomer stabilizer e.g., hydroquinone or a dicarboxylic acid, such as ascorbic acid in about 0.02 weight percent or less of the composition.
- a monomer stabilizer e.g., hydroquinone or a dicarboxylic acid
- ascorbic acid in about 0.02 weight percent or less of the composition.
- a small amount of ethyl alcohol in about one weight percent or less can also be present to help solubilize the ascorbic acid.
- the polymer powder part can also contain a radiopaquing agent, e.g., zirconium oxide or barium sulfate, present in about 5-15 weight percent of the composition, to distinguish the cement from bone during subsequent X-ray analysis and monitoring of the implanted device.
- a radiopaquing agent e.g., zirconium oxide or barium sulfate
- Both the polymer powder and monomer parts can also contain a non-toxic pigmented coloring agent e.g., chlorophyll, present in less than 0.1 weight percent, to enable easy identification in the surgical room during handling and preparation.
- a non-toxic pigmented coloring agent e.g., chlorophyll
- an antibiotic can be included in the polymer powder part, e.g., gentamicin sulfate, or tetracycline, present in about 1-2 weight percent or less, to prevent bacterial infection in the periprosthetic area.
- the separately packaged polymer powder can be sterilized prior to use with, e.g., gamma radiation; the monomer can be sterilized by e.g., sterile microfiltration; and the package containing the polymer part can be sterilized by e.g., ethylene oxide.
- the contents of the polymer powder and monomer parts are mixed in an area having an exhaust system in the surgical room just prior to application. All sterile instruments are used in the mixing procedure.
- the monomer is added to the polymer powder during mixing at room temperature being careful not to entrap air and create air voids. Care must be taken in handling the monomer since it is volatile and flammable.
- the polymerization of the monomer begins which binds together the polymer producing a dough-like mass over a 1-2 minute period.
- the mass is kneaded to a desirable consistency and then placed into the bone cavity, which has been previously washed with cold saline soution and dried, under a slight pressure, by sterile gloved hand, sterile spatula, or by a syringe applicator to force the cement into the spongy areas of the bone to eliminate "air pockets" between the bone cavity and the cement.
- the reason for this is that the cement is not an adhesive and depends upon mechanical interlock of bone, cement and implant surfaces for good fixation.
- the implant device is then firmly inserted into the bone cavity and the excess cement removed. The implant is held firmly in place until complete curing occurs in about a 7-8 minute period. The rest of the arthroplastic structure is then assembled.
- the cement useful herein contains a bisphosphonate admixed with a polymeric base.
- polymers that can be used as the polymeric base for fixation of bone implants are polyacrylic acid ester and polymethylacrylic acid ester types, e.g., polymethacrylate and polymethylmethacrylate, including copolymers of polyacrylic acid ester/polymethacrylic acid ester, and copolymers with polyalkyl- methylmethacrylate.
- Specific polymers include: polyalkylmethacrylates including polymethylmethacrylate (PMMA) and polyethylmethacrylate, polymethacrylate, polymethylmeth- acrylate/polymethacrylate copolymers, copolymers of methyl ⁇ methacrylate including methylmethacrylate/n-decylmeth- aery late/isobornylmethacry late, copolymers and mixtures thereof the above polymers, and the like.
- PMMA polymethylmethacrylate
- polyethylmethacrylate polymethacrylate
- polymethylmeth- acrylate/polymethacrylate copolymers copolymers of methyl ⁇ methacrylate including methylmethacrylate/n-decylmeth- aery late/isobornylmethacry late
- copolymers and mixtures thereof the above polymers and the like.
- a very useful polymer is polymethylmethacrylate.
- an effective amount of biphosphonate in the cement necessary to achieve therapeutic effectiveness will vary with the age, size, sex and condition of the subject, the nature and severity of the disorder to be treated, and the like; thus, a precise effective amount is best determined by the caregiver.
- an effective amount of biphosphonate is about 0.005 to 10 weight percent of the total cement composition and a particularly useful range is 0.1 to 2 weight percent.
- the method of the invention is useful for preventing defects and disorders in the periprosthetic area of the joint prosthesis which can result in a weakened or loosened structure and/or pain.
- the bisphosphonate-containing cement may be implanted directly at the site to be treated, for example, by injection or surgical implantation.
- Bisphosphonate delivered in cement is useful for maintaining implant fixation, by preventing or delaying the onset of aseptic loosening.
- Solubility of the disodium salt in water is about 200mg/ml as compared to the free acid which is 8 mg/ml.
- the solution pH of the disodium salt at 50 mg/ml. is 8.7, as compared to the free acid which is pH 2.2 at 8 mg/ml.
- the hemipentahydrate salt can be heated between 100-150 degrees C. for 1 -4 hours to produce the hemihydrate.
- the hemihydrate salt can be heated from 150-250 degrees C. for 1 -4 hours to produce the anhydrous salt.
- the obtained titled salt displays a unique X-ray diffraction pattern.
- Solubility of the anhydrous monosodium salt in water is about 300 mg/ml as compared to the free acid which is 8 mg/ml.
- the trihydrate precipitates out of the aqueous solution.
- the solution pH of the monosodium salt at 40 mg/ml. is 4.4, as compared to the free acid which is pH 2.2 at 8 mg/ml.
- PalacosTMR with Gentamicin base cement commercially available, including new formulations with bisphosphonates, e.g., alendronate and calcium alendronate.
- Palacos is a registered trademark of Heraeus Kulzer GmbH Wehrheim, Germany, under license to Schering Plough, Suffolk, England. Part A (Polymer Powder
- Sterilized polymer packet containing:
- Methyl methacrylate (stabilized with hydroquinone) 18.40
- Part B is added to Part A under sterile conditions with simple mixing and 1.186 grams (2 weight percent based on the weight of the cement composition prior to adding the bisphosphonate) of 4-amino-l -hydroxybutylidene- 1 ,1 -bisphosphonic acid monosodium trihydrate (alendronate) is added during the mixing step to achieve a uniform cement mixture containing: Ingredient Grams
- bisphosphonate can be used, for example, to achieve 0.005 to 10 weight percentages of the bone reso ⁇ tion inhibitor in the cement composition.
- Bisphosphonate drugs which prevent bone loss and/or add back lost bone can be evaluated in the ovariectomized rat.
- This animal model is well established in the art (see, for example, Wronski, et al., (1985) "Calcif. Tissue Int.” 7:324-328; Kimmel, et al, (1990) "Calcif. Tissue Int.” 46:101-110; and Durbridge, et al., (1990) "Calcif. Tissue Int.” 47:383-387; these references are hereby inco ⁇ orated in their entirety).
- Wronski, et al., ((1985) "Calcif. Tissue Int.” 45:179-183)) describe the association of bone loss and bone turnover in the ovariectomized rat.
- the bisphosphonate salts applicable in the instant invention are active in this assay.
- PMMA polymethyl-methacrylate
- the opposite side of the rat tibia is treated at about the same time and in the same manner except that the PMMA contains up to about 2 percent by weight of alendronate, either as the calcium or sodium salt, or other pharmaceutically acceptable salt.
- alendronate salt is inco ⁇ orated into the PMMA by simple mixing prior to polymerization until a uniform mixture is achieved.
- the tibia containing the alendronate exhibits no substantial localized inflammation or osteolysis, but instead, exhibits new bone formation in the region of the PMMA particles.
- the alendronate-containing PMMA prevents PMMA particle induced osteolysis and localized inflammation.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96917041A EP0831756A1 (en) | 1995-06-06 | 1996-06-03 | Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices |
AU59734/96A AU5973496A (en) | 1995-06-06 | 1996-06-03 | Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices |
JP9501089A JPH11511041A (en) | 1995-06-06 | 1996-06-03 | Bisphosphonate cement composition to prevent aseptic rocking of orthopedic implants |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47040495A | 1995-06-06 | 1995-06-06 | |
US08/470,404 | 1995-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996039107A1 true WO1996039107A1 (en) | 1996-12-12 |
Family
ID=23867503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/008515 WO1996039107A1 (en) | 1995-06-06 | 1996-06-03 | Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0831756A1 (en) |
JP (1) | JPH11511041A (en) |
AU (1) | AU5973496A (en) |
CA (1) | CA2223450A1 (en) |
WO (1) | WO1996039107A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0833643A1 (en) * | 1995-06-06 | 1998-04-08 | Merck & Co., Inc. | Anhydrous alendronate monosodium salt formulations |
EP0837863A1 (en) * | 1995-06-06 | 1998-04-29 | Merck & Co., Inc. | Disodium alendronate formulations |
US6008207A (en) * | 1998-08-13 | 1999-12-28 | Merck & Co., Inc. | Anhydrous alendronate monosodium salt formulations |
WO2000033849A1 (en) * | 1998-12-04 | 2000-06-15 | Roche Diagnostics Gmbh | Use of ibandronate for promoting osseointegration of endoprostheses |
WO2000064516A1 (en) * | 1999-04-22 | 2000-11-02 | Hydromed Sciences A Division Of Gp Strategies Corporation | Controlled delivery of bisphosphonates |
WO2001008690A1 (en) * | 1999-08-02 | 2001-02-08 | Toray Industries, Inc. | Insertion stabilizers for implants |
EP1150684A1 (en) * | 1999-02-09 | 2001-11-07 | Sloan-Kettering Institute For Cancer Research | Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts |
WO2002004038A1 (en) * | 2000-07-12 | 2002-01-17 | Hopital Orthopedique De La Suisse Romande | Active biocoating for bone implant |
WO2003008425A1 (en) * | 2001-07-16 | 2003-01-30 | Universite Paris 13 | Novel bisphosphonate derivatives, their preparation methods and uses |
WO2003045454A2 (en) * | 2001-11-29 | 2003-06-05 | Kathy Rzeszutek | Resorption-controlled bone implants |
EP1383509A1 (en) * | 2001-04-03 | 2004-01-28 | The Royal Alexandra Hospital for Children | A drug for use in bone grafting |
DE102005023094A1 (en) * | 2005-05-13 | 2006-11-16 | Nies, Berthold, Dr. | Bioactive bone cement e.g. for implantation into bones, made by adding small amounts of polymerizable monomers containing anionic groups which cause cement surface to mineralize after being incubated in simulated body fluid |
WO2008040763A1 (en) * | 2006-10-05 | 2008-04-10 | Novartis Ag | Pharmaceutical compositions comprising bisphosphonates |
AU2006202509B2 (en) * | 2005-06-22 | 2008-06-05 | Heraeus Medical Gmbh | Polymethylmethacrylate bone cement |
AU2006202371B2 (en) * | 2005-07-07 | 2008-08-21 | Heraeus Medical Gmbh | Dyed polymethyl methacrylate bone cement and process for its production |
US7674454B2 (en) * | 2004-03-06 | 2010-03-09 | Innovata Limited | Enzyme-prodrug therapy for prosthetic joint repair |
US8182789B2 (en) | 2006-01-20 | 2012-05-22 | Nihon Medi-Physics Co., Ltd. | Intermediate compound of technetium nitride complex for radiodiagnostic imaging |
US8431199B2 (en) | 2009-06-18 | 2013-04-30 | Heraeus Kulzer Gmbh | Container containing the PMMA powder fraction of a two-component system made up of PMMA powder component and MMA monomer component |
US8882740B2 (en) | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
US8889165B2 (en) * | 2007-02-14 | 2014-11-18 | Graftys | Injectable calcium-phosphate cement releasing a bone resorption inhibitor |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201200868D0 (en) * | 2012-01-19 | 2012-02-29 | Depuy Int Ltd | Bone filler composition |
KR102647578B1 (en) * | 2023-04-17 | 2024-03-15 | 주식회사 여명건설 | Concrete composition for high functional precast retaining wall pannel and retaining wall construction method using the high functional precast retaining wall pannel manufactured by the same |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE672205A (en) | 1963-03-18 | 1966-05-10 | ||
US4621077A (en) | 1982-04-15 | 1986-11-04 | Istituto Gentili S.P.A. | Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom |
US4761406A (en) | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
US4876248A (en) | 1982-07-29 | 1989-10-24 | Sanofi | Anti-inflammatory products derived from methylene-diphosphonic acid, and process for their preparation |
US4922007A (en) | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
US4927814A (en) | 1986-07-11 | 1990-05-22 | Boehringer Mannheim Gmbh | Diphosphonate derivatives, pharmaceutical compositions and methods of use |
US4970335A (en) | 1988-01-20 | 1990-11-13 | Yamanouchi Pharmaceutical Co., Ltd. | (Cycloalkylamino)methylenebis(phosphonic acid) |
US5019651A (en) | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
US5116375A (en) * | 1990-08-27 | 1992-05-26 | Hofmann Aaron A | Knee prosthesis |
US5334626A (en) * | 1992-07-28 | 1994-08-02 | Zimmer, Inc. | Bone cement composition and method of manufacture |
US5356887A (en) * | 1990-01-31 | 1994-10-18 | Merck & Co., Inc. | Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids |
US5409911A (en) * | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
US5488041A (en) * | 1993-04-05 | 1996-01-30 | Sanofi | Method of promoting bone repair using tiludronic disodium salt |
-
1996
- 1996-06-03 AU AU59734/96A patent/AU5973496A/en not_active Abandoned
- 1996-06-03 WO PCT/US1996/008515 patent/WO1996039107A1/en not_active Application Discontinuation
- 1996-06-03 EP EP96917041A patent/EP0831756A1/en not_active Withdrawn
- 1996-06-03 JP JP9501089A patent/JPH11511041A/en active Pending
- 1996-06-03 CA CA 2223450 patent/CA2223450A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE672205A (en) | 1963-03-18 | 1966-05-10 | ||
US4621077A (en) | 1982-04-15 | 1986-11-04 | Istituto Gentili S.P.A. | Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom |
US4876248A (en) | 1982-07-29 | 1989-10-24 | Sanofi | Anti-inflammatory products derived from methylene-diphosphonic acid, and process for their preparation |
US4761406A (en) | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
US4927814A (en) | 1986-07-11 | 1990-05-22 | Boehringer Mannheim Gmbh | Diphosphonate derivatives, pharmaceutical compositions and methods of use |
US4970335A (en) | 1988-01-20 | 1990-11-13 | Yamanouchi Pharmaceutical Co., Ltd. | (Cycloalkylamino)methylenebis(phosphonic acid) |
US4922007A (en) | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
US5356887A (en) * | 1990-01-31 | 1994-10-18 | Merck & Co., Inc. | Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids |
US5019651A (en) | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
US5116375A (en) * | 1990-08-27 | 1992-05-26 | Hofmann Aaron A | Knee prosthesis |
US5334626A (en) * | 1992-07-28 | 1994-08-02 | Zimmer, Inc. | Bone cement composition and method of manufacture |
US5409911A (en) * | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
US5488041A (en) * | 1993-04-05 | 1996-01-30 | Sanofi | Method of promoting bone repair using tiludronic disodium salt |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0837863A1 (en) * | 1995-06-06 | 1998-04-29 | Merck & Co., Inc. | Disodium alendronate formulations |
EP0837863A4 (en) * | 1995-06-06 | 1999-06-16 | Merck & Co Inc | Disodium alendronate formulations |
EP0833643A4 (en) * | 1995-06-06 | 1999-06-23 | Merck & Co Inc | Anhydrous alendronate monosodium salt formulations |
EP0833643A1 (en) * | 1995-06-06 | 1998-04-08 | Merck & Co., Inc. | Anhydrous alendronate monosodium salt formulations |
US6008207A (en) * | 1998-08-13 | 1999-12-28 | Merck & Co., Inc. | Anhydrous alendronate monosodium salt formulations |
US6680307B1 (en) * | 1998-12-04 | 2004-01-20 | Roche Diagnostics Gmbh | Use of ibandronate for promoting osseointegration of endoprostheses |
WO2000033849A1 (en) * | 1998-12-04 | 2000-06-15 | Roche Diagnostics Gmbh | Use of ibandronate for promoting osseointegration of endoprostheses |
EP1614422A3 (en) * | 1998-12-04 | 2009-02-18 | Boehringer Mannheim Gmbh | Ibandronate for the promotion of osseointegration of endoprostheses |
EP1150684A4 (en) * | 1999-02-09 | 2005-06-15 | Sloan Kettering Institutefor C | Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts |
EP1150684A1 (en) * | 1999-02-09 | 2001-11-07 | Sloan-Kettering Institute For Cancer Research | Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts |
WO2000064516A1 (en) * | 1999-04-22 | 2000-11-02 | Hydromed Sciences A Division Of Gp Strategies Corporation | Controlled delivery of bisphosphonates |
US6692758B1 (en) * | 1999-08-02 | 2004-02-17 | Toray Industries, Inc. | Insertion stabilizers for implants |
WO2001008690A1 (en) * | 1999-08-02 | 2001-02-08 | Toray Industries, Inc. | Insertion stabilizers for implants |
WO2002004038A1 (en) * | 2000-07-12 | 2002-01-17 | Hopital Orthopedique De La Suisse Romande | Active biocoating for bone implant |
EP1383509A1 (en) * | 2001-04-03 | 2004-01-28 | The Royal Alexandra Hospital for Children | A drug for use in bone grafting |
EP1383509A4 (en) * | 2001-04-03 | 2005-10-26 | Royal Alexandra Hosp Children | A drug for use in bone grafting |
AU2002244520B2 (en) * | 2001-04-03 | 2007-05-24 | The Royal Alexandra Hospital For Children | A drug for use in bone grafting |
WO2003008425A1 (en) * | 2001-07-16 | 2003-01-30 | Universite Paris 13 | Novel bisphosphonate derivatives, their preparation methods and uses |
WO2003045454A2 (en) * | 2001-11-29 | 2003-06-05 | Kathy Rzeszutek | Resorption-controlled bone implants |
WO2003045454A3 (en) * | 2001-11-29 | 2003-08-07 | Kathy Rzeszutek | Resorption-controlled bone implants |
US7674454B2 (en) * | 2004-03-06 | 2010-03-09 | Innovata Limited | Enzyme-prodrug therapy for prosthetic joint repair |
WO2006122678A2 (en) * | 2005-05-13 | 2006-11-23 | Innotere Gmbh | Bioactive bone cement and method for the production thereof |
WO2006122678A3 (en) * | 2005-05-13 | 2007-09-27 | Berthold Nies | Bioactive bone cement and method for the production thereof |
DE102005023094A1 (en) * | 2005-05-13 | 2006-11-16 | Nies, Berthold, Dr. | Bioactive bone cement e.g. for implantation into bones, made by adding small amounts of polymerizable monomers containing anionic groups which cause cement surface to mineralize after being incubated in simulated body fluid |
US8741982B2 (en) | 2005-05-13 | 2014-06-03 | Innotere Gmbh | Bioactive bone cement and method for the production thereof |
AU2006202509B2 (en) * | 2005-06-22 | 2008-06-05 | Heraeus Medical Gmbh | Polymethylmethacrylate bone cement |
AU2006202371B2 (en) * | 2005-07-07 | 2008-08-21 | Heraeus Medical Gmbh | Dyed polymethyl methacrylate bone cement and process for its production |
US8182789B2 (en) | 2006-01-20 | 2012-05-22 | Nihon Medi-Physics Co., Ltd. | Intermediate compound of technetium nitride complex for radiodiagnostic imaging |
WO2008040763A1 (en) * | 2006-10-05 | 2008-04-10 | Novartis Ag | Pharmaceutical compositions comprising bisphosphonates |
US8889165B2 (en) * | 2007-02-14 | 2014-11-18 | Graftys | Injectable calcium-phosphate cement releasing a bone resorption inhibitor |
US8431199B2 (en) | 2009-06-18 | 2013-04-30 | Heraeus Kulzer Gmbh | Container containing the PMMA powder fraction of a two-component system made up of PMMA powder component and MMA monomer component |
US8882740B2 (en) | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
Also Published As
Publication number | Publication date |
---|---|
EP0831756A1 (en) | 1998-04-01 |
AU5973496A (en) | 1996-12-24 |
CA2223450A1 (en) | 1996-12-12 |
JPH11511041A (en) | 1999-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0831756A1 (en) | Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices | |
CA2188030C (en) | Use of bisphophonates for inhibiting bone resorption following implantation of orthopedic prosthesis | |
AU693541B2 (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
US5733564A (en) | Method of treating endo-osteal materials with a bisphosphonate solution | |
JP3062001B2 (en) | Use of bisphosphonic acid derivatives for the preparation of a pharmaceutical composition intended to promote bone repair and the corresponding pharmaceutical composition | |
AU2002244520B2 (en) | A drug for use in bone grafting | |
CA2508085A1 (en) | Implant improving local bone formation | |
EP0675723A1 (en) | Bisphosphonate/estrogen therapy for treating and preventing bone loss | |
AU2002244520A1 (en) | A drug for use in bone grafting | |
EP1208850A1 (en) | Pastes with the sustained release of osteogenesis promoter | |
WO2001049295A1 (en) | Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification | |
KR20020027562A (en) | Drug for treating tractures | |
RU2325170C1 (en) | Bio-composition material applied for osteoplasty | |
CA2183764C (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
MXPA96005327A (en) | Use of certain derivatives of acidometanisphisphonic to prevent the loosening of protesis and the emigration of proteins | |
AU9745901A (en) | Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis | |
MXPA96004968A (en) | Use of bisphosphonates to inhibit bone rebassion after the implantation of orthopedic protesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996917041 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 501089 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2223450 Country of ref document: CA Ref country code: CA Ref document number: 2223450 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996917041 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996917041 Country of ref document: EP |